Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 108Stomach Neoplasms 68Pancreatic Neoplasms 33Neoplasms 24Lymphoma, Large B-Cell, Diffuse 22Carcinoma, Non-Small-Cell Lung 21Neoplasm Metastasis 18Rectal Neoplasms 17Colonic Neoplasms 17Esophageal Neoplasms 16Parkinson Disease 4, Autosomal Dominant Lewy Body 13Adenocarcinoma 13Carcinoma, Hepatocellular 12Ovarian Neoplasms 10Biliary Tract Neoplasms 9Adenocarcinoma Of Esophagus 9Esophageal Squamous Cell Carcinoma 8Cholangiocarcinoma 8Gastrointestinal Neoplasms 7Lymphoma, Non-Hodgkin 6Endometrial Neoplasms 6Gallbladder Neoplasms 5Advanced Solid Tumors 5Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Recurrence 4Carcinoma, Pancreatic Ductal 4Breast Neoplasms 4Advanced Solid Tumor 4Solid Tumors 3

Interventions

magrolimab 1Oxaliplatin 1Nivolumab 1Leucovorin 1Fluorouracil 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Unresectable Colorectal Cancer × Oxaliplatin × Clear all
NCT06540261 2024-09-19

The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer

Ono Pharmaceutical Co., Ltd.

Phase 1 Active not recruiting
65 enrolled
Gastrointestinal

Unresectable Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡